Evaluation of New Markers in Type 3 Angioedema

CHU Brugmann University Hospital

Status: Completed

Conditions: Angio Edema

Treatments: Diagnostic Test: Factor XII dosage; Genetic: p.Thr328Lys mutation detection; Diagnostic Test: Videocapillaroscopy

Study type: Interventional

Funder types: Other

Identifiers

NCT03917680

CHUB-angiodema

Details and patient eligibility

About

Angioedema is a common condition, with multiple etiologies.

Type 3 angioedema is caused by an increase in kininogenase activity responsible for an increased production of bradykinin. In some cases, it may be associated with clotting factor 12 mutations. However, other genetic abnormalities remain to be identified.

Clinically, this angioedema type 3 is similar to types 1 and 2. The patient's vital prognosis is good if the diagnosis is made and if they have access to the appropriate treatment. Otherwise a significant morbidity is associated with it, hence the importance of being able to define a diagnostic marker.

Videocapillaroscopy might be able to highlight abnormalities in the microcirculation of patients with a clinical display of angioedema.

The purpose of this study is to highlight markers allowing to make an early diagnosis of angioedema. Functional analysis of factor XII in patients with symptoms of angioedema may be an interesting marker for diagnosis.

Microcirculation abnormalities will also be evaluated by videocapillaroscopy, which may be another indicator of the disease.

Enrollment: 32 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Population of patients treated within the CHU Brugmann Hospital for an angioedema (and control group of healthy individuals)

Exclusion criteria

• None

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

32 participants in 6 patient groups

Type III angioedema

Experimental group

Description:

White angioedema. Positive for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.

Treatment:

Diagnostic Test: Videocapillaroscopy

Diagnostic Test: Factor XII dosage

Genetic: p.Thr328Lys mutation detection

Idiopathic angioedema

Experimental group

Description:

White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.

Treatment:

Diagnostic Test: Videocapillaroscopy

Diagnostic Test: Factor XII dosage

Genetic: p.Thr328Lys mutation detection

Type I or II angioedema

Experimental group

Description:

White angioedema. Negative for Factor XII mutation. C1-inhibitors anomaly. Not caused by IEC.

Treatment:

Diagnostic Test: Videocapillaroscopy

Diagnostic Test: Factor XII dosage

Genetic: p.Thr328Lys mutation detection

Post IEC (conversion enzyme inhibitors) angioedema

Experimental group

Description:

White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Caused by IEC.

Treatment:

Diagnostic Test: Videocapillaroscopy

Diagnostic Test: Factor XII dosage

Genetic: p.Thr328Lys mutation detection

Histaminic angioedema

Experimental group

Description:

Red angioedema.Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.

Treatment:

Diagnostic Test: Videocapillaroscopy

Diagnostic Test: Factor XII dosage

Genetic: p.Thr328Lys mutation detection

Control

Other group

Description:

Healthy individuals, no angioedema.

Treatment:

Diagnostic Test: Videocapillaroscopy